baricitinib in dermatology: expanding therapeutic horizons beyond alopecia areata

Context :janus kinases (jak), in coordination with signal transducer and activator of transcription (stat) proteins, form a network of pathogenic pathways that regulate inflammatory immune responses. dysregulation of the jak-stat pathway has been implicated in the pathogenesis of numerous inflammatory dermatoses. consequently, jak inhibitors have emerged as a novel therapeutic modality in dermatology. this narrative review aims to summarize the current evidence on baricitinib, a first-generation jak inhibitor, focusing on its efficacy, safety, and therapeutic applications in dermatological diseases, particularly alopecia areata (aa) and atopic dermatitis (ad). the review also explores its emerging and off-label uses in other chronic, treatment-refractory dermatoses. evidence acquisition :a comprehensive literature search was conducted across pubmed, scopus, and google scholar using predefined keywords: baricitinib in dermatology, baricitinib in alopecia areata, and efficacy of baricitinib in dermatological conditions. data from systematic reviews, randomized controlled trials (rcts), case series, and case reports were included. additional information was derived from united states food and drug administration (fda) approval documents, clinicaltrials.gov, and the prescribing leaflet. particular emphasis was placed on evaluating the drug's accessibility and relevance within the indian clinical context. results :baricitinib received fda approval on june 13, 2022, for the treatment of moderate to severe aa, marking a significant advancement in targeted immunotherapy. it has also demonstrated efficacy in ad and was extensively utilized during the covid-19 pandemic due to its antiviral and anti-inflammatory properties. emerging evidence supports its potential in refractory conditions such as vitiligo, dermatomyositis, systemic sclerosis, lichen planus, and pyoderma gangrenosum, though further prospective studies are warranted. conclusions :baricitinib represents a major advancement in the management of immune-mediated dermatologic diseases. its expanding clinical utility underscores the importance of continued research to optimize dosing strategies, evaluate long-term safety, and define its role across a broader spectrum of inflammatory skin disorders.